Nitto Denko
Nitto Denko Corporation, founded in 1918 and headquartered in Osaka, Japan, is a leading diversified materials manufacturer that operates internationally. The company specializes in the production of adhesive tapes, including double-sided tapes, masking tapes, and sealing materials, catering to various industries such as automotive, construction, electronics, and healthcare. Nitto Denko also offers a wide range of films, including surface protective films and fluoroplastic films, as well as electronic products like flexible printed circuit boards. Its medical product line features transdermal drug delivery patches and adhesive surgical items. The company leverages its core technologies, including polymer synthesis and adhesion, to create approximately 13,500 high-value-added products. With a strong focus on research and development, Nitto Denko collaborates with organizations like CAGE Bio Inc. to innovate in areas such as transdermal formulations.
C3Nano is the developer of the solution-based, transparent conductive inks and films as direct replacements for indium tin oxide (ITO). C3Nano is the performance leader in Transparent Conductor Films (TCFs) and Activegrid silver nanowire (AgNW) solution-based inks for the touch sensor and display industry. They have raised $37 million in funding to date, which has enabled the company to quickly achieve best in class ink formulations and expanded production capabilities. C3Nano is headquartered in Silicon Valley with an industry-leading manufacturing base in Korea. Founded in 2010, it is headquartered in Hayward, California.
Algotochip specializes in the design of digital chips, specifically Systems on a Chip (SOCs). The company streamlines the design process by significantly reducing both time and costs associated with chip development. Their innovative technology enables the partitioning of customer C-code into optimized modules, which then generate all necessary hardware and corresponding software components for a complete application solution. By transforming behavioral algorithms into architecture-specific code, and subsequently into Register Transfer Level (RTL) and GDS-II formats, Algotochip effectively turns complex algorithms into functional chips, thus enhancing efficiency in digital chip design.
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.
Avecia is a leading private biotechnology company, operating through its OligoMedicines business, focused on the development and manufacture of innovative biotechnology-based medicines. With a long history of technological innovation, they work closely with their customers who are typically biotechnology or pharmaceutical companies, helping them achieve fast progress into, and through, the clinical development programme.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.